IP Library Granted Patent US 8,163,356
Granted Patent B2
US 8,163,356 · App. 12/161,210 · Granted Apr 24, 2012

Products

Assignee: P2i Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,356
App. No.
12/161,210
Granted
Apr 24, 2012
Kind
B2
Abstract

A laboratory consumable having a polymeric coating, coating formed by exposing said consumable to pulsed plasma for a sufficient period of time to allow a polymeric layer to form on the surface of the laboratory consumable, said plasma comprising a compound of formula (I) where R 1 , R 2 , R 3 and R 4 are as defined in the specification. Consumables of this type show significantly reduced liquid sample retention, maximum sample recovery and ultra non-binding properties, as well as oil and water-repellency.

Claims (36)

1. A laboratory consumable comprising a polymeric coating, wherein the polymeric coating is formed by exposing the consumable to a pulsed plasma for a period of time sufficient to form a polymeric layer on a surface of the laboratory consumable, the plasma comprising a compound of formula (I)

where R 1 , R 2 and R 3 are selected independently from hydrogen, alkyl, haloalkyl or aryl optionally substituted by halogen; and R 4 is a group XR 5 where R 5 is an alkyl or haloalkyl group and X is a bond; or R 4 is C(O)O(CH 2 ) n Y where n is an integer of 1 to 10 and Y is a bond, an alkyl or haloalkyl group, or a sulphonamide group; or R 4 is (O) p R 6 (O) q (CH 2 ) t where R 6 is aryl optionally substituted by halogen, p is 0 or 1, q is 0 or 1 and t is 0 or an integer of 1 to 10, provided that where q is 1, t is other than 0.

2. The laboratory consumable of claim 1 selected from the group consisting of pipette tips, filtration membranes, microplates, immunoassay products, centrifuge tubes, microtubes, specimen tubes, test tubes, blood collection tubes, flat based tubes, aseptically produced containers, general labware, burettes, cuvettes, needles, hypodermic syringes, sample vials/bottles, screw cap containers, and weighing bottles.

3. The laboratory consumable of claim 1 , which is a pipette tip.

4. The laboratory consumable of claim 1 , wherein the exposing to the pulsed plasma takes place within a plasma deposition chamber.

5. The laboratory consumable of claim 1 , wherein the compound of formula (I) is a compound of formula (II)

CH 2 ═CH—R 5   (II)

where R 5 is an alkyl or haloalkyl group.

6. The laboratory consumable of claim 1 , wherein the compound of formula (I) is a compound of formula (III)

CH 2 ═CR 7 C(O)O(CH 2 ) n R 5   (III)

where n is an integer of 1 to 10; R 5 is an alkyl or haloalkyl group; and R 7 is hydrogen, C 1-10 alkyl, or C 1-10 haloalkyl.

7. The laboratory consumable of claim 6 , wherein the compound of formula (III) is a compound of formula (IV)

where R 7 is hydrogen, C 1-10 alkyl, or C 1-10 haloalkyl; and x is an integer of 1 to 9.

8. The laboratory consumable of claim 7 , wherein the compound of formula (IV) is 1H,1H,2H,2H-heptadecafluorodecylacrylate.

9. A method for reducing liquid sample retention by a laboratory consumable, the method comprising a preliminary step of applying a continuous power plasma to the laboratory consumable and a subsequent step of exposing the consumable to a pulsed plasma in a gaseous state for a period of time sufficient for a polymeric layer to form on both the inside and outside surfaces of the laboratory consumable thereby reducing the liquid sample retention by the consumable, the plasma comprising a compound of formula (I)

where R 1 , R 2 and R 3 are independently selected from hydrogen, alkyl, haloalkyl or aryl optionally substituted by halogen; and R 4 is a group X—R 5 where R 5 is an alkyl or haloalkyl group and X is a bond; or R 4 is C(O)O(CH 2 ) n Y where n is an integer of 1 to 10 and Y is a bond, an alkyl or haloalkyl group, or a sulphonamide group; or R 4 is (O) p R 6 (O) q (CH 2 ) t where R 6 is aryl optionally substituted by halogen, p is 0 or 1, q is 0 or 1 and t is 0 or an integer of 1 to 10, provided that where q is 1, t is other than 0.

10. The method of claim 9 , wherein the laboratory consumable is placed in a plasma deposition chamber, a glow discharge is ignited within the chamber, and a voltage is applied as a pulsed field.

11. The method of claim 10 , wherein the applied voltage is at a power of 40 W to 500 W.

12. The method of claim 10 , wherein the voltage is pulsed in a sequence in which the ratio of the time on to time off is about 1:500 to 1:1500.

13. The method of claim 12 , wherein the voltage is pulsed in a sequence where power is on for 20 μs to 50 μs, and off for 1000 μs to 30000 μs.

14. The method of claim 10 , wherein the voltage is applied as a pulsed field for a period of 30 seconds to 90 minutes.

15. The method of claim 14 , wherein the voltage is applied as a pulsed field for 5 minutes to 60 minutes.

16. The method of claim 9 , wherein the preliminary step is conducted in the presence of an inert gas.

17. The method of claim 10 , wherein the compound of formula (I) in gaseous form is fed into the plasma at a rate of from 80 mg/minute to 300 mg/minute, while the pulsed voltage is applied.

18. The method of claim 9 , wherein the plasma is created with a voltage at an average power of 0.001 W/m 3 to 500 W/m 3 .

19. The method of claim 18 , wherein the plasma is created with a voltage at an average power of 0.001 W/m 3 to 100 W/m 3 .

20. The method of claim 18 , wherein the plasma is created with a voltage at an average power of 0.005 W/m 3 to 0.5 W/m 3 .

21. The method of claim 9 , wherein the compound of formula (I) is a compound of formula (II)

CH 2 ═CH—R 5   (II)

where R 5 is an alkyl or haloalkyl group.

22. The method of claim 9 , wherein the compound of formula (I) is a compound of formula (III)

CH 2 ═CR 7 C(O)O(CH 2 ) n R 5   (III)

where n is an integer of 1 to 10, R 5 is an alkyl or haloalkyl group, and R 7 is hydrogen, C 1-10 alkyl, or C 1-10 haloalkyl.

23. The method of claim 22 , wherein the compound of formula (III) is a compound of formula (IV)

where R 7 is hydrogen, C 1-10 alkyl, or C 1-10 haloalkyl, and x is an integer of 1 to 9.

24. The method of claim 23 wherein the compound of formula (IV) is 1H,1H,2H,2H-heptadecafluorodecyl acrylate.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2022
From: CLYDESDALE BANK PLC
To: P2I LTD.
Reel/Frame 061480/0861 →
SECURITY INTEREST Recorded Jul 2, 2020
From: P2I LTD
To: CLYDESDALE BANK PLC
Reel/Frame 053111/0780 →
SECURITY INTEREST Recorded Apr 4, 2017
From: P2I LTD
To: CLYDESDALE BANK PLC
Reel/Frame 041846/0599 →
CONFIRMATION OF RELEASE OF DEBENTURE Recorded Feb 17, 2017
From: GLAS TRUST CORPORATION LIMITED
To: P2I LIMITED
Reel/Frame 041746/0186 →
CONFIRMATION OF DEBENTURE Recorded Nov 18, 2015
From: P2I LIMITED
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 037129/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2008
From: COULSON, STEPHEN
To: P2I LTD.
Reel/Frame 021442/0717 →
Priority Claims (1)
GB 0601113.4 · Jan 20, 2006 · national
Continuity (2)
Provisional Application 60762249 · Jan 26, 2006
Related Publication 20100234524A1 · Sep 16, 2010